Immunitybio Inc
IBRX2.140USD
0.000
Close 12/26, 16:00（ET）Quotes delayed by 15 min
2.11BMarket Cap
LossP/E TTM
More Details of Immunitybio Inc Company
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
Immunitybio Inc Info
Ticker SymbolIBRX
Company nameImmunitybio Inc
IPO dateJul 28, 2015
CEOAdcock (Richard)
Number of employees680
Security typeOrdinary Share
Fiscal year-endJul 28
Address3530 John Hopkins Court
CitySAN DIEGO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92121
Phone18446965235
Websitehttps://immunitybio.com/
Ticker SymbolIBRX
IPO dateJul 28, 2015
CEOAdcock (Richard)
Company Executives of Immunitybio Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Patrick Soon-Shiong, M.D.
Dr. Patrick Soon-Shiong, M.D.
Executive Chairman of the Board, Global Chief Scientific and Medical Officer
Executive Chairman of the Board, Global Chief Scientific and Medical Officer
29.55M
-15.98%
Mr. Richard Adcock
Mr. Richard Adcock
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
334.42K
--
Mr. Michael D. Blaszyk
Mr. Michael D. Blaszyk
Independent Director
Independent Director
265.58K
--
Ms. Cheryl L. Cohen
Ms. Cheryl L. Cohen
Lead Independent Director
Lead Independent Director
200.62K
--
Dr. Linda Maxwell, M.D.
Dr. Linda Maxwell, M.D.
Independent Director
Independent Director
--
--
Mr. David Sachs
Mr. David Sachs
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Barry J. Simon, M.D.
Dr. Barry J. Simon, M.D.
Chief Corporate Affairs, Director
Chief Corporate Affairs, Director
--
--
Ms. Christobel E. Selecky
Ms. Christobel E. Selecky
Independent Director
Independent Director
--
--
Gen. (Retd.) Wesley Clark
Gen. (Retd.) Wesley Clark
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Patrick Soon-Shiong, M.D.
Dr. Patrick Soon-Shiong, M.D.
Executive Chairman of the Board, Global Chief Scientific and Medical Officer
Executive Chairman of the Board, Global Chief Scientific and Medical Officer
29.55M
-15.98%
Mr. Richard Adcock
Mr. Richard Adcock
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
334.42K
--
Mr. Michael D. Blaszyk
Mr. Michael D. Blaszyk
Independent Director
Independent Director
265.58K
--
Ms. Cheryl L. Cohen
Ms. Cheryl L. Cohen
Lead Independent Director
Lead Independent Director
200.62K
--
Dr. Linda Maxwell, M.D.
Dr. Linda Maxwell, M.D.
Independent Director
Independent Director
--
--
Mr. David Sachs
Mr. David Sachs
Chief Financial Officer
Chief Financial Officer
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2024
FY2023
FY2022
FY2021
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
14.21M
96.40%
Europe
531.00K
3.60%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Tue, Nov 18
Updated: Tue, Nov 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Cambridge Equities, L.P.
62.97%
Soon-Shiong (Patrick)
3.00%
The Vanguard Group, Inc.
2.80%
BlackRock Institutional Trust Company, N.A.
1.74%
Jane Street Capital, L.L.C.
1.30%
Other
28.18%
Shareholders
Shareholders
Proportion
Cambridge Equities, L.P.
62.97%
Soon-Shiong (Patrick)
3.00%
The Vanguard Group, Inc.
2.80%
BlackRock Institutional Trust Company, N.A.
1.74%
Jane Street Capital, L.L.C.
1.30%
Other
28.18%
Shareholder Types
Shareholders
Proportion
Corporation
62.97%
Investment Advisor
7.95%
Individual Investor
3.45%
Investment Advisor/Hedge Fund
3.03%
Research Firm
2.26%
Hedge Fund
1.42%
Bank and Trust
0.11%
Pension Fund
0.06%
Other
18.74%
Institutional Shareholding
Updated: Sun, Oct 5
Updated: Sun, Oct 5
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
452
133.12M
13.51%
+38.56M
2025Q2
428
738.71M
78.16%
+109.34M
2025Q1
440
618.65M
87.38%
-10.66M
2024Q4
423
621.25M
74.01%
+7.18M
2024Q3
400
607.11M
84.02%
-2.53M
2024Q2
394
600.23M
83.10%
-13.23M
2024Q1
370
604.61M
90.46%
-1.82M
2023Q4
363
595.85M
89.24%
+717.13K
2023Q3
366
588.92M
88.35%
+213.08M
2023Q2
362
368.64M
84.54%
-18.27M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Cambridge Equities, L.P.
614.63M
65.02%
+117.19M
+23.56%
Apr 21, 2025
Soon-Shiong (Patrick)
35.16M
3.72%
--
--
Apr 21, 2025
The Vanguard Group, Inc.
21.76M
2.3%
+1.46M
+7.17%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
15.28M
1.62%
+3.67M
+31.60%
Jun 30, 2025
Jane Street Capital, L.L.C.
7.72M
0.82%
+7.59M
+5866.36%
Jun 30, 2025
State Street Investment Management (US)
7.62M
0.81%
+31.66K
+0.42%
Jun 30, 2025
Geode Capital Management, L.L.C.
5.78M
0.61%
+1.49M
+34.69%
Jun 30, 2025
Woodline Partners LP
3.45M
0.36%
+774.00
+0.02%
Jun 30, 2025
Simon (Barry J. M.D.)
3.24M
0.34%
--
--
Apr 21, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Virtus LifeSci Biotech Products ETF
1.2%
iShares Genomics Immunology and Healthcare ETF
0.47%
State Street SPDR S&P Biotech ETF
0.29%
ProShares Ultra Nasdaq Biotechnology
0.27%
Invesco Nasdaq Biotechnology ETF
0.22%
Direxion Daily S&P Biotech Bull 3X Shares
0.16%
Goldman Sachs Innovate Equity ETF
0.08%
Pacer WealthShield ETF
0.04%
iShares Russell 2000 Growth ETF
0.03%
JPMorgan BetaBuilders US Small Cap Equity ETF
0.03%
View more
Virtus LifeSci Biotech Products ETF
Proportion1.2%
iShares Genomics Immunology and Healthcare ETF
Proportion0.47%
State Street SPDR S&P Biotech ETF
Proportion0.29%
ProShares Ultra Nasdaq Biotechnology
Proportion0.27%
Invesco Nasdaq Biotechnology ETF
Proportion0.22%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.16%
Goldman Sachs Innovate Equity ETF
Proportion0.08%
Pacer WealthShield ETF
Proportion0.04%
iShares Russell 2000 Growth ETF
Proportion0.03%
JPMorgan BetaBuilders US Small Cap Equity ETF
Proportion0.03%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Immunitybio Inc?
The top five shareholders of Immunitybio Inc are:
Cambridge Equities, L.P. holds 614.63M shares, accounting for 65.02% of the total shares.
Soon-Shiong (Patrick) holds 35.16M shares, accounting for 3.72% of the total shares.
The Vanguard Group, Inc. holds 21.76M shares, accounting for 2.30% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 15.28M shares, accounting for 1.62% of the total shares.
Jane Street Capital, L.L.C. holds 7.72M shares, accounting for 0.82% of the total shares.
Cambridge Equities, L.P. holds 614.63M shares, accounting for 65.02% of the total shares.
Soon-Shiong (Patrick) holds 35.16M shares, accounting for 3.72% of the total shares.
The Vanguard Group, Inc. holds 21.76M shares, accounting for 2.30% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 15.28M shares, accounting for 1.62% of the total shares.
Jane Street Capital, L.L.C. holds 7.72M shares, accounting for 0.82% of the total shares.
What are the top three shareholder types of Immunitybio Inc?
The top three shareholder types of Immunitybio Inc are:
Cambridge Equities, L.P.
Soon-Shiong (Patrick)
The Vanguard Group, Inc.
Cambridge Equities, L.P.
Soon-Shiong (Patrick)
The Vanguard Group, Inc.
How many institutions hold shares of Immunitybio Inc (IBRX)?
As of 2025Q3, 452 institutions hold shares of Immunitybio Inc, with a combined market value of approximately 133.12M, accounting for 13.51% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -64.64%.
What is the biggest source of revenue for Immunitybio Inc?
In FY2024, the -- business generated the highest revenue for Immunitybio Inc, amounting to -- and accounting for --% of total revenue.
